biosimilars

News

Sandoz launches first biosimilar Tysabri in US

Biogen is facing biosimilar competition to its multiple sclerosis therapy Tysabri in the US for the first time, as Sandoz enters the market.

News

FDA plan will cut testing requirements for biosimilars

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilar medicines to market as a way to cut US drug prices.

R&D

How Europe can harness the full potential of biosimilars

Biosimilars - clinically equivalent alternatives to original biologic drugs - play a vital role in addressing unmet health needs.

News

IPO plan evaporates as private equity firm buys Stada

Stada has confirmed it isn't going ahead with an IPO, as its two private equity owners have just agreed to sell a majority stake to a third.

News

Stada revives talk of an IPO – if conditions improve

Germany's Stada has said it may make another attempt to seek a public listing in the autumn, after delaying its plans earlier this year.

Patients

Biosimilars: Unlocking access, closing the cost divide

Every day, countless Americans are forced to choose between meeting basic needs such as food, housing, or transportation and paying for their medications.

Sandoz launches first biosimilar Tysabri in US

FDA plan will cut testing requirements for biosimilars

How Europe can harness the full potential of biosimilars

IPO plan evaporates as private equity firm buys Stada

Stada revives talk of an IPO – if conditions improve

Biosimilars: Unlocking access, closing the cost divide

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

biosimilars

Editor's Picks